Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.

Hunt MA, Li D, Hay MP, Currie MJ, Robinson BA, Patterson AV, Dachs GU.

J Gene Med. 2012 Jan;14(1):62-74. doi: 10.1002/jgm.1635.

PMID:
22147660
2.

Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.

Sekar TV, Foygel K, Willmann JK, Paulmurugan R.

Gene Ther. 2013 May;20(5):529-37. doi: 10.1038/gt.2012.66. Epub 2012 Aug 23.

PMID:
22914496
3.
4.

Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.

Benouchan M, Do Nascimento F, Perret GY, Colombo BM.

Int J Oncol. 2006 Feb;28(2):457-62.

PMID:
16391801
5.

Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery.

Benouchan M, Do Nascimento F, Sebbah-Louriki M, Salzmann JL, Crépin M, Perret GY, Colombo BM.

Biochem Biophys Res Commun. 2003 Nov 28;311(4):822-8.

PMID:
14623255
6.

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK.

Eur J Cancer. 1995 Dec;31A(13-14):2362-70. Erratum in: Eur J Cancer 1996 Jan;32A(1):186.

PMID:
8652270
7.

Virus-directed enzyme prodrug therapy using CB1954.

Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ.

Anticancer Drug Des. 1999 Dec;14(6):461-72. Review.

PMID:
10834268
8.

Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA.

Cancer Res. 2002 Mar 1;62(5):1425-32.

9.

Bystander or no bystander for gene directed enzyme prodrug therapy.

Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV.

Molecules. 2009 Nov 10;14(11):4517-45. doi: 10.3390/molecules14114517. Review.

10.

Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.

McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF.

Gene Ther. 1998 Aug;5(8):1061-9.

11.

Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.

Yu B, Zhang Y, Zhan Y, Zha X, Wu Y, Zhang X, Dong Q, Kong W, Yu X.

Oncol Rep. 2011 Jul;26(1):255-64. doi: 10.3892/or.2011.1285. Epub 2011 Apr 28.

PMID:
21573500
12.

Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.

Nishihara E, Nagayama Y, Narimatsu M, Namba H, Watanabe M, Niwa M, Yamashita S.

Anticancer Res. 1998 May-Jun;18(3A):1521-5.

PMID:
9673364
13.

Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.

Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, Selby PJ, Chester JD.

Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43. Epub 2011 Aug 12.

PMID:
21836632
14.
15.

Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.

Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI.

Clin Exp Pharmacol Physiol. 2004 Nov;31(11):811-6. Review.

PMID:
15566399
16.

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2010 Mar 1;79(5):678-87. doi: 10.1016/j.bcp.2009.10.008. Epub 2009 Oct 21.

PMID:
19852945
17.

E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.

Mitchell DJ, Minchin RF.

Cancer Gene Ther. 2008 Nov;15(11):758-64. doi: 10.1038/cgt.2008.47. Epub 2008 Jul 4.

PMID:
18600257
18.

Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.

Eaton JD, Perry MJ, Todryk SM, Mazucco RA, Kirby RS, Griffiths JR, Dalgleish AG.

Gene Ther. 2001 Apr;8(7):557-67.

19.

Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.

White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, Melcher AA, Pandha HS, Harrington KJ.

Gene Ther. 2008 Mar;15(6):424-33. Epub 2007 Dec 13.

PMID:
18079753
20.

Supplemental Content

Support Center